CompletedNCT00868699
Lurasidone alone for depression in bipolarity
About this title
Read the official source — NCT00868699Researchers compared lurasidone and placebo to find out how the approaches affected depression symptoms in people with bipolarity type I during a depressive episode.
Medication studyAges 18–75Multiple countries
Understand this study
What did researchers investigate?
Researchers compared lurasidone and placebo to find out how the approaches affected depression symptoms in people with bipolarity type I during a depressive episode.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 75 years. Other eligibility criteria applied.
- Listed locations
- Escondido and 54 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateApril 2009
- Recruitment status
- Completed
- Enrollment listed in the registry
- 505
- Sponsor
- Sumitomo Pharma America, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, France, Czechia, ...
- Age range
- From 18 Years to 75 Years
- Official registry ID
- NCT00868699
- Official title
Show the full official title
A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Fixed-Flexible Dose, Parallel-Group Study of Lurasidone for the Treatment of Bipolar I Depression
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Escondido, United States · Garden Grove, United States · Oceanside, United States
49 more locations
- Orange, United States
- Pico Rivera, United States
- San Diego, United States
- Aurora, United States
- Bradenton, United States
- Maitland, United States
- Tampa, United States
- West Palm Beach, United States
- Oak Brook, United States
- Lake Charles, United States
- Baltimore, United States
- Albuquerque, United States
- Cedarhurst, United States
- Rochester, United States
- Raleigh, United States
- Cleveland, United States
- Philadelphia, United States
- Austin, United States
- Kolejni 429-5, Czechia
- Brno - Mesto, Czechia
- Litoměřice, Czechia
- Prague, Czechia
- Nîmes, France
- Orvault, France
- Tirupati, India
- Vijaywada, India
- Ahmedabad, India
- Bangalore, India
- Nashik, India
- Jaipur, India
- Lucknow, India
- Bucdresti, Romania
- Bucharest, Romania
- Cluj-Napoca, Romania
- Craiova, Romania
- Oradea, Romania
- Saint Petersburg, Russia
- Cape Town, W. Cape, South Africa
- Paarl, W. Cape, South Africa
- Port Elizabeth, E. Cape, South Africa
- Pretoria, Gauteng, South Africa
- Vereeniging, Free State, South Africa
- Donetsk, Ukraine
- Odesa, Ukraine
- Poltava, Ukraine
- Simferopol, Ukraine
- Vinnitsia, Ukraine
- Czechia
- Russia
Questions about this study
What did researchers investigate?
Researchers compared lurasidone and placebo to find out how the approaches affected depression symptoms in people with bipolarity type I during a depressive episode.
Who is behind this study?
The study sponsor is Sumitomo Pharma America, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including lurasidone and Placebo.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 75 years. Other eligibility criteria applied.
